Conformable TAG胸主动脉支架前瞻性多中心试验的5年长期结果
该研究为前瞻性多中心试验,评估Conformable TAG(CTAG)胸主动脉支架治疗降主动脉瘤的5年安全性和有效性。共纳入66例患者,5年内动脉瘤相关死亡率为6.1%,器械相关再干预率为7.6%,50.0%患者瘤囊回缩,17.9%瘤囊扩张。
要点
- CTAG支架治疗降主动脉瘤5年动脉瘤相关死亡率低(6.1%),再干预率低(7.6%)。
- 5年时50.0%患者瘤囊回缩,17.9%扩张,32.1%稳定(5mm阈值)。
- 无支架断裂或压缩,无III型连接部内漏,近端内漏罕见。
核心结论
- CTAG装置行胸主动脉腔内修复术5年内动脉瘤相关死亡率和再干预率均较低。
- 近端内漏罕见,多数患者5年时瘤囊回缩或稳定。
研究设计与样本
- 前瞻性多中心试验,评估CTAG装置治疗降主动脉瘤的安全性和有效性。
- 2009年10月至2011年9月共纳入66例患者(51例关键臂和15例持续准入)。
- 每年进行影像学随访至5年,核心影像实验室评估瘤囊大小、器械完整性和内漏。
主要发现
- 5年内5例(7.6%)需要器械相关再干预。
- 4例(6.1%)死于动脉瘤相关原因,其中1例在术后30天内死亡。
- 5年研究期间共24例(36.3%)死亡。
- 7例(10.6%)发生卒中或短暂性脑缺血发作,其中1例早期卒中(术后第28天)。
- 6例(9.1%)观察到假体或组件间迁移,但无III型连接部内漏;无支架断裂或压缩。
临床怎么用
- CTAG装置用于降主动脉瘤的胸主动脉腔内修复术,5年结果支持其安全性和有效性。
- 术后5年内需定期影像学随访,监测内漏、瘤囊变化和器械迁移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Gore conformable TAG thoracic endoprosthesis (CTAG) was engineered to enhance conformability in the thoracic aorta and has demonstrated greater deployment accuracy and wall apposition than the original TAG device. The Food and Drug Administration approved the CTAG in 2011 based on the 1-year results of the pivotal trial for the CTAG device. In the present report, we have documented the outcomes for those patients through 5 years. METHODS: The CTAG aneurysm study was a prospective, multicenter trial that assessed the safety and effectiveness of the CTAG device as treatment of descending thoracic aortic aneurysms. Follow-up imaging assessments consisted of radiographs and computed tomography at annual intervals through 5 years. A core imaging laboratory was used to assess the aneurysm size, device integrity, and endoleaks. RESULTS: A total of 66 patients were enrolled (51 pivotal arm patients and 15 continued access patients) from October 2009 through September 2011. The baseline characteristics, procedural characteristics, and outcomes through 2 years were reported previously. Through 5 years, five patients (7.6%) had required device-related reintervention (one type Ia endoleak or contained rupture of the descending thoracic aorta, one type Ib endoleak, two indeterminate endoleaks, and one thoracic aortic pseudoaneurysm). Four patients (6.1%) had died of aneurysm-related causes, with one death occurring within 30 days of the index procedure. A total of 24 patients (36.3%) had died during the 5-year study period. Seven patients (10.6%) had experienced stroke or transient ischemic attack through 5 years, with one early stroke (postoperative day 28). Prosthesis or intercomponent migration was observed in six patients (9.1%) through 5 years; however, no patient had developed a type III junctional endoleak. No stent-graft fracture or compression was observed through 5 years. At 5 years, 14 patients (50.0%) showed sac regression, 5 (17.9%) showed sac expansion, and 9 (32.1%) showed sac stability using on a 5-mm threshold for change. CONCLUSIONS: Thoracic endovascular aortic repair with the CTAG device was associated with low rates of aneurysm-related mortality and reintervention through 5 years. Proximal endoleak was rare, and most patients showed sac regression or stability at 5 years after the initial thoracic endovascular aortic repair.
引用
- Jordan WD, Desai N, Letter AJ, et al. Long-term outcomes of the conformable TAG thoracic endoprosthesis in a prospective multicenter trial. J Vasc Surg. 2021. PMID: 34022380. doi:10.1016/j.jvs.2021.04.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。